Stereotactic radiation therapy: Changing treatment paradigms for stage i nonsmall cell lung cancer

Current Opinion in Oncology

Volumn 23, Issue 2, 2011, Pages 133-139

  Palma, David ^a,b   Senan, Suresh ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

nonsmall cell lung cancer; stage I; stereotactic body radiation therapy; surgery

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC TREATMENT;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RADIOSURGERY;

EID: 79952002656     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328341ee11     Document Type: Article

References (69)

1. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: clinical experience of the first thirty-one patients. Acta Oncol 1995; 34:861-870.
2. Cykert S, Dilworth-Anderson P, Monroe MH, et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed earlystage lung cancer. JAMA 2010; 303:2368-2376.
3. Cykert S, Dilworth-Anderson P, Monroe MH, et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed earlystage lung cancer. JAMA 2010; 303:2368-2376. (Pubitemid 32706145)
4. Detterbeck FC, Gibson CJ. Turning gray: the natural history of lung cancer over time. J Thorac Oncol 2008; 3:781-792.
5. Haasbeek CJ, Slotman BJ, Senan S. Radiotherapy for lung cancer: clinical impact of recent technical advances. Lung Cancer 2009; 64:1-8.
6. Keall P. 4-Dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol 2004; 14:81-90. (Pubitemid 38168957)
7. Grills IS, Hugo G, Kestin LL, et al. Image-guided radiotherapy via daily online cone-beam CT substantially reduces margin requirements for stereotactic lung radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70:1045-1056. (Pubitemid 351296103)
8. Fowler JF, Tome WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004; 60:1241.
9. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 70:685-692.
10. Nguyen NP, Garland L, Welsh J, et al. Can stereotactic fractionated radiation therapy become the standard of care for early stage nonsmall cell lung carcinoma. Cancer Treat Rev 2008; 34:719-727.
11. Bradley JD, El Naqa I, Drzymala RE, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys 2010; 77:1146-1150.
12. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101:1623-1631. (Pubitemid 39318910)
13. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I nonsmall cell lung cancer: updated results of .257. patients in a Japanese multiinstitutional study. J Thorac Oncol 2007; 2:S94-S100. (Pubitemid 47183602)
14. Park C, Papiez L, Zhang S, et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70:847-852. (Pubitemid 351199730)
15. Fowler JF. Linear quadratics is alive and well: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2008; 70:847-852). Int J Radiat Oncol Biol Phys 2008; 72:957.
16. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303:1070-1076.
17. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27:3290-3296.
18. Palma D, Senan S, Haasbeek CJA, et al. Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of 3D-conformal and volumetric modulated arc therapy techniques. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]
19. Kimura T, Matsuura K, Murakami Y, et al. CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? Int J Radiat Oncol Biol Phys 2006; 66:483-491. (Pubitemid 44332732)
20. Trovo M, Linda A, El Naqa I, et al. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer 2010; 69:77-85.
21. Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol 2009. [Epub ahead of print]
22. Takeda A, Kunieda E, Takeda T, et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2008; 70:1057-1065. (Pubitemid 351296119)
23. Haasbeek CJ, Senan S, Smit EF, et al. Critical review of nonsurgical treatment options for stage I nonsmall cell lung cancer. Oncologist 2008; 13:309-319. (Pubitemid 351679907)
24. Grutters JPC, Kessels AGH, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for nonsmall cell lung cancer: a meta-analysis. Radiother Oncol 2010; 95: 32-40.
25. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24:4833-4839. (Pubitemid 46630909)
26. Song SY, Choi W, Shin SS, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 2009; 66:89-93.
27. Bogart JA. Stereotactic body radiation therapy for early-stage lung cancer: are we 'all in'. J Thorac Oncol 2010; 5:927-929.
28. Senan S, Haasbeek NJ, Smit EF, Lagerwaard FJ. Stereotactic radiotherapy for centrally located early-stage lung tumors. J Clin Oncol 2007; 25:464; author reply 465. (Pubitemid 350003007)
29. Guckenberger M, Heilman K, Wulf J, et al. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol 2007; 85:435-442. (Pubitemid 350213147)
30. Bral S, Gevaert T, Linthout N, et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a phase II trial. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]
31. Radiation Therapy Oncology Group. RTOG 0813: Seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. http://www.rtog.org/members/protocols/0813/0813.pdf. [Accessed 17 September 2010]
32. Verbakel WF, Senan S, Cuijpers JP, et al. Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. Radiother Oncol 2009; 93:122-124.
33. RTOG 0618: A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with operable stage I/II non-small cell lung cancer http://www.rtog.org/members/protocols/0618/0618.pdf. [Accessed 30 September 2010]
34. A randomized clinical trial of either surgery or stereotactic radiotherapy for early stage (IA) lung cancer (ROSEL). http://www. clinicaltrials.gov/ct2/show/NCT00687986. [Accessed 30 September 2010]
35. Kyas I, Hof H, Debus J, et al. Prediction of radiation-induced changes in the lung after stereotactic body radiation therapy of nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 67:768-774. (Pubitemid 46215862)
36. Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:796-801.
37. Pettersson N, Nyman J, Johansson KA. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of nonsmall cell lung cancer: a dose- and volume-response analysis. Radiother Oncol 2009; 91:360-368.
38. Hoppe BS, Laser B, Kowalski AV, et al. Acute skin toxicity following stereotactic body radiation therapy for stage I nonsmall-cell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys 2008; 72:1283-1286.
39. Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009; 93:408-413.
40. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA nonsmall cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol 2009; 4:1.
41. Dahele M, Pearson S, Purdie T, et al. Practical considerations arising from the implementation of lung stereotactic body radiation therapy (SBRT) at a comprehensive cancer center. J Thorac Oncol 2008; 3:1332-1341.
42. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010; 76:326-332.
43. Holmberg L, Sandin F, Bray F, et al. National comparisons of lung cancer survival in England, Norway and Sweden 2001-2004: differences occur early in follow-up. Thorax 2010; 65:436-441.
44. Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010. [Epub ahead of print]
45. Trans-Tasman Radiation Oncology Group. Hypofractionated radiotherapy (stereotactic) versus conventional radiotherapy for inoperable early stage I nonsmall cell lung cancer (NSCLC). .2010. http://clinicaltrials.gov/ct2/show/ NCT01014130. [Accessed 9 November 2010]
46. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]
47. Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I nonsmall-cell lung cancer. J Clin Oncol 2010; 28:928-935.
48. Bosco LF, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol 2010; 63:64-74.
49. Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation therapy versus surgical resection for stage I nonsmall cell lung cancer. J Thorac Cardiovasc Surg 2010; 140:377-386.
50. Louie AV, Rodrigues G, Hannouf M, et al. Stereotactic body radiotherapy versus surgery for stage I NSCLC: a Markov model-based decision analysis. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]
51. Janssen-Heijnen M, Schipper RM, Razenberg PPA, et al. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21:105-113. (Pubitemid 29028028)
52. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007; 25:5570-5577.
53. Tyldesley S, Roques TW, Erridge S. General practitioner assessment of stage and performance status in lung cancer patients at a population level: implications for prognosis and radiotherapy needs analyses. Lung Cancer 2007; 57:381-388. (Pubitemid 47285420)
54. Tyldesley S, Zhang-Salomons J, Groome PA, et al. Association between age and the utilization of radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 2000; 47:469-480. (Pubitemid 30236390)
55. Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing highrisk cancer operation: a national study. J Am Coll Surg 2007; 205:729-734. (Pubitemid 350116627)
56. Wouters MW, Siesling S, Jansen-Landheer M, et al. Variation in treatment and outcome in patients with nonsmall cell lung cancer by region, hospital type and volume in the Netherlands. Eur J Surg Oncol 2010; 36 (Suppl 1):S83-S92.
57. Haasbeek CJ, Lagerwaard FJ, Antonisse ME, et al. Stage I nonsmall cell lung cancer in patients aged > or 75 years: outcomes after stereotactic radiotherapy. Cancer 2010; 116:406-414.
58. Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery. Chest 2007; 132:161S-177S.
59. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respirat J 2009; 34:17-41.
60. Palma D, Lagerwaard F, Rodrigues G, et al. Curative treatment of stage I nonsmall cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. In: 2010 ASTRO multidisciplinary symposium in thoracic oncology.
61. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995; 109:120-129.
62. Pasini F, Verlato G, Durante E, et al. Persistent excess mortality from lung cancer in patients with stage I nonsmall-cell lung cancer, disease-free after.5. years. Br J Cancer 2003; 88:1666-1668. (Pubitemid 36760406)
63. Donington JS, Miller DL, Rowland CC, et al. Subsequent pulmonary resection for bronchogenic carcinoma after pneumonectomy. Ann Thorac Surg 2002; 74:154-158; discussion 158-159.
64. Haasbeek CJ, Lagerwaard FJ, de Jaeger K, et al. Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer 2009; 115:587-594.
65. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help: a SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008; 65:156-163.
66. McNeil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer. N Engl J Med 1978; 299:1397-1401. (Pubitemid 9092483)
67. Kenny PM, King MT, Viney RC, et al. Quality of life and survival in the 2 years after surgery for non-small-cell lung cancer. J Clin Oncol 2008; 26:233-241.
68. Van der Voort van Zyp NC, Prevost JB, van der Holt B, et al. Quality of life after stereotactic radiotherapy for stage I nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 2010; 77:31-37.
69. Senan S, Gundy C, Haasbeek CJ, et al. Health-related quality of life (HRQOL) after stereotactic body radiotherapy (SBRT) for stage I nonsmall cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2010; 28 (Suppl 15): 7079.